<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611754</url>
  </required_header>
  <id_info>
    <org_study_id>EFC_7276</org_study_id>
    <nct_id>NCT00611754</nct_id>
  </id_info>
  <brief_title>Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>Phase II Study of Oxaliplatin in Combination With 5-Fluorouracil (5-FU) in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU)
      in patients with advanced inoperable or metastatic head and neck cancer and to investigate
      the safety profile of this regimen in the above indication and consider other criteria of
      efficacy (clinical benefit, survival)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU) in patients with advanced inoperable or metastatic head and neck cancer.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety profile of this regimen in the above indication and consider other criteria of efficacy (clinical benefit, survival)</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, 5-FU</intervention_name>
    <description>Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.</description>
    <other_name>Eloxatin®, Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged 18-70 years, with inoperable locally advanced or metastatic squamous cell
        carcinoma of the head and neck (stage III-IV) histologically proven, no prior chemo and/or
        hormone therapy for metastatic disease or local recurrence (adjuvant or neo-adjuvant
        chemotherapy or radio-chemotherapy was allowed if finished since more than 6 months before
        inclusion and cisplatinum total dose used &lt; or=to 300 mg/m² or carboplatinum total dose
        used &lt; or=to 200mg/m²), at least 1 target lesion (measurable in 2 dimensions &gt; or=to 20 mm
        on computed tomography (CT) or magnetic resonance imaging (MRI) evaluated &lt; 15 days before
        start of study treatment, outside of irradiated fields),performance status (PS) &lt; or =to 2
        World Health Organization (WHO), weight loss &lt; 5% normal weight,hemoglobin &gt; or =to 10
        g/dL, neutrophils &gt; or =to 2000/mm3, platelets &gt; or =to 100,000/mm3 , creatinine &lt; or =to
        1.5 x upper limit of normal (ULN), bilirubin &lt; or =to .5 x ULN, alanine amino-transferase
        (ALT)/aspartate amino-transferase (AST)&lt; or =to 2.5 x ULN (5 x ULN if liver metastases),
        clotting: prothrombin time (PT) &gt; or =to 60%. Written informed consent signed by patient
        and doctor prior to all study procedures -

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Billon</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>January 28, 2008</last_update_submitted>
  <last_update_submitted_qc>January 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nathalie Billon/Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

